Evaluation of plasma activity of matrix metalloproteinase-2 and -9 in dogs with myxomatous mitral valve disease

American Journal of Veterinary Research

Volumn 72, Issue 8, 2011, Pages 1022-1028

  Ljungvall, Ingrid ^a   Rajamäki, Minna M ^b   Crosara, Serena ^c   Olsen, Lisbeth H ^d   Kvart, Clarence ^a   Borgarelli, Michele ^e   Höglund, Katja ^a   Häggström, Jens ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GELATINASE A; GELATINASE B; TROPONIN I;

ARTERIAL PRESSURE; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOG DISEASE; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; FEMALE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; MALE; MITRAL VALVE DISEASE; MYXOMATOUS MITRAL VALVE DISEASE; NONHUMAN; SEX DIFFERENCE; ZYMOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; DOG DISEASES; DOGS; ECHOCARDIOGRAPHY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME PRECURSORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART; HEART RATE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SPECIES SPECIFICITY; TROPONIN I;

ANIMALIA; CANIS FAMILIARIS;

EID: 80052769292     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.72.8.1022     Document Type: Article

References (46)

1. Pelouch V, Dixon IM, Golfman L, et al. Role of extracellular matrix proteins in heart function. Mol Cell Biochem 1993;129:101-120.
2. Spinale FG. Matrix metalloproteinases: regulation and dysregu-lation in the failing heart. Circ Res 2002;90:520-530.
3. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
4. Coker ML, Doscher MA, Thomas C V, et al. Matrix metallopro-teinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 1999;277:H777-H787.
5. Thomas C V, Coker ML, Zellner JL, et al. Increased matrix me-talloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998;97:1708-1715.
6. Spinale FG, Gunasinghe H, Sprunger PD, et al. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail 2002;8:S332-S338.
7. Buchanan J. Chronic valvular disease (endocardiosis) in dogs. Adv Vet Sci Comp Med 1977;21:75-106.
8. Thrusfeld M, Aitken C, Darke P. Observations on breed and sex in relation to canine heart valve incompetence. J Small Anim Pract 1985;26:709-717.
9. Dell'italia LJ, Balcells E, Meng QC, et al. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol 1997;273:H961-H970.
10. Falk T, Jönsson L, Olsen LH, et al. Arteriosclerotic changes in the myocardium, lung, and kidney in dogs with chronic congestive heart failure and myxomatous mitral valve disease. Cardio-vasc Pathol 2006;15:185-193.
11. Pat B, Killingsworth CR, Denney T, et al. Dissociation between cardiomyocyte function and remodeling with {beta}-adrenergic receptor blockade in isolated canine mitral regurgitation. Am J Physiol Heart Circ Physiol 2008;295:H2321-H2327.
12. Aupperle H, Thielebein J, Kiefer B, et al. Expression of genes encoding matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in normal and diseased canine mitral valves. J Comp Pathol 2009;140:271-277.
13. Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998;98:1728-1734.
14. Ljungvall I, Höglund K, Tidholm A, et al. Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs. J Ve t Intern Med 2010;24:153-159.
15. Thomas W, Gaber C, Jacobs G, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med 1993;7:247-252.
16. Pedersen HD, Kristensen B, Norby B, et al. Echocardiographic study of mitral valve prolapse in Dachshunds. Zentralbl Veteri-narmed A 1996;43:103-110.
17. Olsen L, Martinussen T, Pedersen HD. Early echocardiographic predictors of myxomatous mitral valve disease in Dachshunds. Vet Rec 2003;152:293-297.
18. Hansson K, Häggström J, Kvart C, et al. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in Cavalier King Charles Spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 2002;43:568-575.
19. Bélanger MC. Echocardiography. In: Ettinger SJ, Feldman EC, eds. Textbook of veterinary internal medicine. 6th ed. St Louis: Elsevier Saunders, 2005;311-326.
20. Cornell C, Kittleson M, Della Torre P, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004;18:311-321.
21. Grossman W, Jones D, McLaurin L P. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56-64.
22. Rajamäki MM, Järvinen AK, Sorsa T, et al. Clinical fndings, bronchoalveolar lavage fuid cytology and matrix metallo-proteinase-2 and -9 in canine pulmonary eosinophilia. Vet J 2002;163:168-181.
23. Oyama MA, Solter P F. Validation of an immunoassay for measurement of canine cardiac troponin-I. J Vet Cardiol 2004;6:17-24.
24. Oyama MA, Sisson DD. Cardiac troponin-I concentration in dogs with cardiac disease. J Vet Intern Med 2004;18:831-839.
25. Kjelgaard-Hansen M, Kristensen AT, Jensen AL. Evaluation of a commercially available enzyme-linked immunosor-bent assay (ELISA) for the determination of C-reactive protein in canine serum. J Vet Med A Physiol Pathol Clin Med 2003;50:164-168.
26. Haggstrom J, Hansson K, Karlberg B, et al. Plasma concentration of atrial natriuretic peptide in relation to severity of mitral regurgitation in Cavalier King Charles Spaniels. Am J Vet Res 1994;55:698-703.
27. Bland M. Multifactorial methods. In: Bland M, ed. An introduction to medical statistics. 2nd ed. Oxford, England: Oxford University Press, 1995;322-323.
28. Nagatomo Y, Carabello BA, Coker ML, et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol 2000;278:H151-H161.
29. Anne W, Willems R, Roskams T, et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fbrillation. Cardiovasc Res 2005;67:655-666.
30. Hojo Y, Ikeda U, Ueno S, et al. Expression of matrix metallopro-teinases in patients with acute myocardial infarction. Jpn Circ J 2001;65:71-75.
31. Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-217.
32. Spinale FG, Coker ML, Thomas C V, et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 1998;82:482-495.
33. Coker ML, Thomas C V, Clair MJ, et al. Myocardial matrix me-talloproteinase activity and abundance with congestive heart failure. Am J Physiol 1998;274:H1516-H1523.
34. Borgarelli M, Tarducci A, Zanatta R, et al. Decreased systolic function and inadequate hypertrophy in large and small breed dogs with chronic mitral valve insuffciency. J Vet Intern Med 2007;21:61-67.
35. Kittleson M, Brown W. Regurgitant fraction measured by using the proximal isovelocity surface area method in dogs with chronic myxomatous mitral valve disease. J Vet Intern Med 2003;17:84-88.
36. Egner B, Erhardt W, Henke J, et al. Indications for blood pressure measurement. In: Egner B, Carr A, Brown S, eds. Essential facts of blood pressure in dogs and cats: a reference guide. 3rd ed. Babenhausen, Germany: Beate Egner Vet Verlag, 2003;21-22.
37. Khan A, Moe G W, Nili N, et al. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. J Am Coll Cardiol 2004;43:68-76.
38. Kim HE, Dalal SS, Young E, et al. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 2000;106:857-866.
39. Peterson JT, Hallak H, Johnson L, et al. Matrix metalloprotein-ase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001;103:2303-2309.
40. Blaustein AS, Hoit BD, Wexler L F, et al. Characteristics of chronic left ventricular dysfunction induced by coronary emboliza-tion in a canine model. Am J Cardiovasc Pathol 1995;5:32-48.
41. Gill RM, Jones BD, Corbly AK, et al. Cardiac diastolic dysfunction in conscious dogs with heart failure induced by chronic coronary microembolization. Am J Physiol Heart Circ Physiol 2006;291:H3154-H3158.
42. Sundström J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Fram-ingham Heart Study. Circulation 2004;109:2850-2856.
43. Koh KK, Ahn JY, Kang MH, et al. Effects of hormone replacement therapy on plaque stability, infammation, and fbrinolysis in hypertensive or overweight postmenopausal women. Am J Cardiol 2001;88:1423-1426.
44. Potier M, Karl M, Elliot SJ, et al. Response to sex hormones differs in atherosclerosis-susceptible and -resistant mice. Am J Physiol Endocrinol Metab 2003;285:E1237-E1245.
45. Oyama MA, Chittur S V. Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. Am J Vet Res 2006;67:1307-1318.
46. Mischke R, Waterston M, Eckersall PD. Changes in C-reactive protein and haptoglobin in dogs with lymphatic neoplasia. Vet J 2007;174:188-192.